Market Trends of Global Peptide Synthesis Industry
The Segment for Solid-phase Peptide Synthesis (SPPS) Holds a Significant Market Share
Solid-phase peptide synthesis (SPPS) is a pivotal technique in the production of peptides, where the peptide chain is built on a solid support, typically a resin. This method has revolutionized peptide synthesis by streamlining automation and purification processes, making it a staple in research and industrial applications.
SPPS is especially notable for its efficiency in producing longer peptides, such as those used in diabetes treatments, which can be challenging to synthesize using liquid-phase methods due to complex purification requirements.
The growing demand for peptides has led to considerable expansion in SPPS production capabilities. For instance, in January 2024, WuXi AppTec reported commissioning new peptide manufacturing plants in Changzhou and Taixing, China. This expansion increased its total reactor volume to 32,000 liters, addressing the increased global demand for peptide therapeutics.
Similarly, in September 2023, CordenPharma International inaugurated an expanded SPPS manufacturing facility at CordenPharma Colorado, enhancing its capacity to meet global demand. This facility is the largest SPPS production site worldwide, with upgraded technology that boosts efficiency and throughput.
SPPS remains a critical technology in peptide production, particularly for the pharmaceutical industry. The increasing demand for peptide drugs and the need for more sustainable manufacturing practices drive significant innovations and expansions in SPPS. As the market continues to address environmental challenges and improve efficiency, SPPS is set to maintain its pivotal role in drug development and other applications.
North America is Expected to Record Significant Growth Over the Forecast Period
The North American market for peptide synthesis is expected to grow due to factors such as strong R&D investment in biotechnology and pharmaceuticals, advanced healthcare infrastructure, the presence of major pharmaceutical and biopharmaceutical companies, and the increasing prevalence of chronic diseases.
The presence of a large number of academic and research institutes and heavy funding from the government and private entities are expected to result in several new developments in the region, further adding to the growth of the market as many of these research institutes are working on novel therapies involving therapeutic peptides.
The rising funding from the National Institute of Health on genomic research is anticipated to propel market growth over the forecast period. For instance, in September 2023, the National Institute of Health (NIH) allocated around USD 5.8 million for a five-year initiative to establish an educational center focusing on computational genomics and data science. This aims to broaden educational and research horizons, particularly targeting students from historically marginalized backgrounds in the biomedical field. Therefore, such huge funding for genomics is anticipated to increase the adoption of peptide synthesis for genomics.
Some of the world's largest pharmaceutical and biopharmaceutical companies are present in the United States. In September 2023, Corden Pharma, a key company in active pharmaceutical ingredients (APIs), excipients, drug products, and packaging services, inaugurated an expanded commercial peptide production capacity with newly upgraded facilities at its Colorado site. This expansion reinforced Corden Pharma's status as the premier large-scale peptide CDMO partner for the pharmaceutical and biotech industries.
Therefore, owing to the high burden of chronic diseases, well-established and robust healthcare infrastructure, rising investments in genomics and proteomics, and significant investment in research and development activities, the United States is expected to hold a significant share of the peptide synthesis market over the forecast period.
